Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.
R J SeagerMaria-Fernanda SenosainErik Van RoeyShuang GaoPaul DePietroMary K NeslineDurga Prasad DashShengle ZhangHeidi KoStephanie B HastingsKyle C StricklandRebecca A PrevisTaylor J JensenMarcia EisenbergBrian J CaveneyEric A SeversonShakti RamkissoonJeffrey M ConroySarabjot PablaPublished in: Journal of translational medicine (2024)
CTA co-expression can be reliably measured using CGIP in solid tumors. As a biomarker, CTAB appears to be independent from PD-L1 expression, suggesting that CTAB represents aspects of tumor immunogenicity not measured by current standard of care testing. Improved OS and ORR for high CTAB NSCLC patients treated with pembrolizumab monotherapy suggests a unique underlying aspect of immune response to these tumor antigens that needs further investigation.
Keyphrases
- small cell lung cancer
- healthcare
- advanced non small cell lung cancer
- poor prognosis
- dendritic cells
- palliative care
- papillary thyroid
- quality improvement
- randomized controlled trial
- squamous cell carcinoma
- risk factors
- binding protein
- chronic pain
- lymph node metastasis
- epidermal growth factor receptor
- affordable care act
- study protocol
- tyrosine kinase